Founded by University of Pittsburgh physician-scientists in 2017, Globin Solutions develops recombinant heme-protein therapeutics, including candidates intended to counter carbon monoxide poisoning. The Baltimore company’s proprietary yeast-based platform produces complex heme proteins at more than 95% purity and also supports research into artificial blood substitutes. Its neuroglobin candidate has received FDA Orphan Drug Designation, while the company advances three therapeutic programs toward clinical development.
Orphan Drug Designation for GSI-1721 (Neuroglobin)
Compliance program
Hemoglobin Oxygen Therapeutics LLCHemoglobin Oxygen Therapeutics develops human and veterinary hemoglobin-based oxygen carriers that increase blood’s ability to transport oxygen. Its Hemopure product is used in South Africa and Russia for acute anemia and remains investigational in the United States, while Oxyglobin was the first veterinary oxygen therapeutic approved in the US and Europe for canine anemia. The company draws on more than 25 years of research and has consolidated production at a facility in Souderton, Pennsylvania, undergoing a multimillion-dollar expansion.541715SOUDERTON, PA
RS BioTherapeutics, IncBased in Cumberland, Maryland, RS BioTherapeutics is a life-sciences company focused on developing medicines for people with pulmonary inflammation. Its lead investigational compound, RSBT-001, is being studied as a steroid-free approach to serious respiratory disease, with development informed by a council of prominent pulmonary specialists.
OxygeniumBorn from combat-medicine experience and an emergency physician’s response to oxygen shortages in the field, Oxygenium develops portable medical oxygen delivery systems. Its patented technology generates continuous, adjustable high-flow oxygen on demand through a chemical cartridge system, offering an alternative to explosive cylinders and power-dependent concentrators. The New York company was founded by trauma surgeon and former IDF combat physician Dr. Ben Alkahe with Ran Miron.New York, NY
BC3 TechnologiesFounded in Baltimore in 2018, minority-owned BC3 Technologies develops and manufactures emergency bleeding-control products, including its FDA-cleared SEAL Hemostatic Wound Spray. The company makes and distributes its products in Maryland, drawing on a leadership team with 35 years of medical-device and drug-manufacturing experience and deep backgrounds in chemistry and emergency care.BALTIMORE, MD